Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
RIPK1 Inhibitor
RIPK1-IN-15 is a potent inhibitor of Receptor Interacting Protein Kinase 1 (RIPK1). This compound demonstrates significant potential in modulating pathways associated with neurodegenerative, autoimmune, and inflammatory diseases. Research applications include the investigation of cell death signaling, inflammation regulation, and therapeutic approaches targeting RIPK1-mediated pathologies. -
RIPK2/ALK2 Inhibitor
RIPK2-IN-1 is a selective inhibitor targeting RIPK2 and ALK2, with an IC50 of 51 nM and 5 nM, respectively. This compound demonstrates substantial efficacy in modulating RIPK2/NOD2 pathways, exhibiting an IC50 of 390 nM in cellular assays. RIPK2-IN-1 is suitable for research applications investigating pathways related to inflammation and immune response mechanisms. -
RIPK1 Inhibitor
RIPK1-IN-39 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 69.40 nM and more than 100-fold selectivity over RIPK3 (IC50 = 6946 nM). This compound effectively prevents necroptosis in HT-22 and HT-29 cell lines by inhibiting the phosphorylation and activation of the RIPK1-RIPK3-MLKL signaling pathway. Additionally, RIPK1-IN-39 has demonstrated neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO), making it a valuable tool for research in acute ischemic stroke (AIS). -
RIPK2 Inhibitor
RIPK2-IN-8 is a selective inhibitor of Receptor-interacting protein kinase 2 (RIPK2) with an IC50 of 11 nM. It shows significant selectivity for RIPK2 over RIPK1 (IC50 > 30,000 nM) and a moderate inhibitory effect on RIPK3 (IC50 = 44.61 nM). By inhibiting the NOD2-RIPK2 signaling pathway, RIPK2-IN-8 reduces the expression of key inflammatory cytokines such as IL-6 and TNFα, demonstrating robust anti-inflammatory properties. Its efficacy in an acute liver injury model indicates potential applications in liver injury and inflammation research. -
RIPK1 Inhibitor
RIPK1-IN-21 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an EC50 value of 14.8 nM. This compound is valuable for research into neurodegenerative, autoimmune, and inflammatory diseases, where modulation of RIPK1 activity may play a critical role. Its potent inhibitory effects enable investigations into the mechanisms of RIPK1-mediated cell death and inflammation. -
RIPK2 Inhibitor
RIPK2-IN-3 is a potent inhibitor of Receptor Interacting Protein Kinase 2 (RIPK2), demonstrating an IC50 of 6.39 μM against recombinant truncated RIPK2. This compound is utilized in research studies focused on inflammation and cancer, providing valuable insights into the pathways regulated by RIPK2. Its specificity makes it a useful tool for evaluating RIPK2's role in various biological processes. -
RIPK1 Inhibitor
RIPK1-IN-14 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 value of 92 nM. This compound demonstrates significant anti-necroptotic effects in a necroptosis model utilizing U937 cells. RIPK1-IN-14 is applicable in research focusing on cell death mechanisms, inflammation, and neurodegenerative diseases. -
RIPK1 Inhibitor
RIPK1-IN-28 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It demonstrates significant biological activity with IC50 values of 0.4 nM and 1.2 nM against human I2.1 and Hepa1-6 cell lines, respectively. This compound is valuable for research applications aimed at elucidating the role of RIPK1 in cell death and inflammatory processes. -
RIPK1 Inhibitor
RIPK1-IN-12 is a potent inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It effectively inhibits necroptosis, with EC50 values of 1.6 nM in human cells and 2.9 nM in mouse cells. This compound is valuable for research applications focused on cell death pathways and related diseases such as neurodegeneration and cancer. -
RIPK1 Inhibitor
RIPK1-IN-11 is a potent and orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1), demonstrating a Kd of 9.2 nM and an IC50 of 67 nM. This compound effectively inhibits necroptosis in human and mouse cells, with an EC50 range of 17-30 nM. Due to its anti-inflammatory properties, RIPK1-IN-11 is valuable in researching the pathophysiology of inflammatory diseases and cell death mechanisms. -
RIPK1 Inhibitor
RIPK1-IN-38 is a potent, orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1), with an IC50 value of 27 nM. It effectively blocks the phosphorylation of RIPK1 and its downstream effectors, RIPK3 and MLKL, thereby exhibiting significant anti-necroptotic activity. This compound demonstrates strong anti-inflammatory effects in models of systemic inflammatory response syndrome (SIRS) and graft-versus-host disease (GVHD). RIPK1-IN-38 is suitable for research into inflammatory and immune-related diseases. -
RIPK1 Inhibitor
RIPK1-IN-13 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 1139 nM. By inhibiting RIPK1, this compound effectively disrupts the necroptosis pathway, making it a valuable tool for investigating the molecular mechanisms underlying inflammatory diseases. Its applications extend to various research areas focused on cell death and inflammatory processes. -
RIPK1 Inhibitor
RIPK1-IN-18 is a selective inhibitor of Receptor-Interacting Protein Kinase 1 (RIPK1). It demonstrates potent activity in modulating cell death and inflammation pathways, making it a valuable tool for investigating the underlying mechanisms of autoimmune diseases. This compound is applicable in research focused on therapeutic strategies for conditions associated with RIPK1-mediated signaling. -
RIPK1 Inhibitor
RIPK1-IN-37 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), which plays a crucial role in apoptosis and inflammation. This compound serves as a ligand for the target protein in the PROTAC LD5097 synthesis, facilitating targeted protein degradation research. Its application extends to studies of cell death pathways and the development of novel therapeutics for diseases involving dysregulated RIPK1 activity. -
RIPK1 Inhibitor
RIPK1-IN-34 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 126.70 nM, demonstrating significant potency and minimal off-target effects on RIPK3 (IC50 > 10,000 nM). This compound provides substantial neuroprotection by preventing the phosphorylation of key proteins involved in the necroptosis pathway, including RIPK1, RIPK3, and MLKL. Notably, RIPK1-IN-34 exhibits neuroprotective effects in the rat middle cerebral artery occlusion (MCAO) model, making it a valuable tool for research focused on mitigating damage in acute ischemic stroke (AIS). -
RIPK1 Inhibitor
RIPK1-IN-16 is a potent, orally active inhibitor of Receptor-Interacting Protein Kinase 1 (RIPK1). It effectively mitigates excessive inflammation by blocking RIPK1-mediated necroptosis. This compound demonstrates protective effects in mouse models against tumor necrosis factor (TNF)-induced systemic inflammatory response syndrome and sepsis, making it a valuable tool for research into inflammatory diseases and cell death pathways. -
RIPK1 Kinase Inhibitor
RIPK1-IN-20 is a potent inhibitor targeting RIPK1 kinase, exhibiting significant enzymatic inhibition with an IC50 value of 59.8 nM. This compound effectively blocks TNFα-induced necroptosis in both human and murine cells, demonstrating EC50 values ranging from 1.06 to 4.58 nM. It serves as a valuable tool for research into cell death pathways and therapeutic interventions in necroptotic diseases. -
RIPK1 Inhibitor
RIPK1-IN-9 is a selective inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It demonstrates potent inhibitory activity in U937 cells with an IC50 of 2 nM, and in L929 cells with an IC50 of 1.3 nM. This compound is valuable for research in cell death, inflammation, and various diseases where RIPK1 is implicated. -
RIPK1 Inhibitor
RIPK1-IN-10 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), a key regulator of cellular apoptosis and necroptosis. This compound is designed for use in biological research applications, particularly in studies focused on cell death pathways, inflammatory responses, and neurodegenerative diseases. Its inhibition of RIPK1 provides a valuable tool for investigating the therapeutic potential of modulating necroptotic processes in various disease models. -
RIPK1 Inhibitor
RIPK1-IN-19 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 of 15 nM. It demonstrates significant protective effects in models of systemic inflammatory response syndrome (SIRS) induced by TNFα, as well as in imiquimod-induced psoriasis models. This compound serves as a valuable tool for investigating the roles of RIPK1 in inflammation and immune system disorders. -
RIPK1 Kinase Inhibitor
KWCN-41 is a selective inhibitor of RIPK1 kinase, exhibiting an IC50 value of 88 nM. This compound specifically targets and inhibits cell necrosis while leaving apoptotic pathways unaffected. Additionally, KWCN-41 demonstrates anti-inflammatory properties, making it a valuable tool for research in cell death mechanisms and inflammation-related studies. -
RIPK1 Inhibitor
RIPK1-IN-24 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 value of 1.3 μM. This compound is utilized in research investigating the role of RIPK1 in inflammatory diseases, making it a valuable tool for studies on cell survival, apoptosis, and signal transduction pathways. Researchers can leverage RIPK1-IN-24 to elucidate the mechanisms underlying inflammation-related pathologies and explore potential therapeutic strategies. -
RIPK1 Inhibitor
RIPK1-IN-35 is a selective and orally bioavailable inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 5.33 nM. This compound exhibits a strong protective effect against necroptosis in both human and murine cell models. It demonstrates significant therapeutic potential in experimental models of TNF-α-induced systemic inflammatory response syndrome and DSS-induced inflammatory bowel disease. RIPK1-IN-35 is valuable for research into inflammatory diseases associated with necroptosis. -
RIP3 Inhibitor
RIPK3-IN-2 is a selective inhibitor of receptor-interacting protein kinase 3 (RIPK3), which plays a crucial role in necroptotic cell death pathways. This compound is utilized in research focused on diseases associated with activated necroptosis, providing insights into the underlying mechanisms of cellular pathology and potential therapeutic interventions. Its ability to modulate RIPK3 activity makes it a valuable tool for studying necrotic processes in various biological contexts. -
RIPK1 Inhibitor
RIPK1-IN-8 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting a potent inhibitory activity with an IC50 value of 4 nM. This compound is valuable for research into inflammatory diseases, providing insights into RIPK1-mediated signaling pathways and their role in inflammation and cell death. Its specificity and efficacy make it a suitable tool for investigating the therapeutic potential of RIPK1 inhibition in various disease models. -
RIPK2 Inhibitor
RIPK2-IN-6 is a selective inhibitor of RIPK2, effectively blocking its phosphorylation and subsequently inhibiting the NF-κB and MAPK signaling pathways. This compound exhibits significant anti-inflammatory and anti-fibrotic properties, demonstrated in Dextran sodium sulfate-induced colitis models in mice. RIPK2-IN-6 is valuable in research exploring therapeutic strategies for inflammatory and fibrotic diseases. -
RIPK2 Inhibitor
RIPK2-IN-5 is a high-affinity inhibitor of receptor-interacting protein kinase 2 (RIPK2), demonstrating an IC50 value of 5.1 nM. This compound exhibits significant anti-inflammatory effects by reducing the secretion of TNF-α in response to MDP in a dose-dependent manner. With moderate stability in human liver microsomes, RIPK2-IN-5 serves as a valuable tool for investigating immune diseases and related therapeutic strategies. -
Caspase-9 Inhibitor
Caspase-9 Inhibitor III (Ac-LEHD-cmk) targets and inhibits caspase-9, a critical component of the apoptotic pathway. This reagent demonstrates protective effects against ischemia-reperfusion-induced myocardial injury, making it valuable for studying cardiac apoptosis and related pathological conditions. It can be utilized in research focused on cellular survival mechanisms and the modulation of programmed cell death. -
Caspase Inhibitor
Ac-FLTD-CMK is a selective inhibitor of inflammatory caspases, specifically targeting caspases-1, -4, -5, and -11, with IC50 values of 46.7 nM, 1.49 μM, and 329 nM, respectively. This compound is derived from gasdermin D (GSDMD) and does not inhibit apoptotic caspases such as caspase-3. Ac-FLTD-CMK is instrumental in research applications focused on inflammatory processes, providing valuable insights into caspase-mediated pathways and their implications in various diseases. -
Caspase-4 inhibitor
Z-LEVD-FMK is a cell-permeable inhibitor of caspase-4, a key player in the apoptotic signaling pathway. This reagent effectively blocks endoplasmic reticulum stress-induced apoptosis in cancer cells, making it a valuable tool for studying cell death mechanisms and developing therapeutic strategies in oncology research. Its specificity for caspase-4 facilitates investigations into its role in various cellular stress responses. -
MDM2 Inhibitor
LQFM030 is a novel small molecule inhibitor of MDM2, primarily targeting the MDM2-p53 interaction to promote cellular apoptosis. It demonstrates concentration-dependent cytotoxicity in K562 cells with an IC50 value of 0.28 mM, inducing G0/G1 phase cell cycle arrest and enhancing Caspase activity. LQFM030 also downregulates the expression of key oncogenes and proteins, including MDM2, MDMX, p73, MYC, and NF-κB. This compound is particularly valuable in cancer research, especially in the study of leukemia. -
Caspase Inhibitor
Z-VAD-CHO is a potent, irreversible inhibitor of caspases, primarily targeting caspase-1 with a Ki value of 0.008 μM. This compound effectively modulates apoptotic pathways and is instrumental in studies related to inflammation and cell death. Z-VAD-CHO is widely utilized in research to investigate the role of caspases in various cellular processes and disease models. -
Caspase-1/3 Inhibitor
Z-YVAD-CMK is a potent inhibitor of caspase-1 and caspase-3, key enzymes involved in the apoptosis and inflammatory processes. By selectively blocking these caspases, Z-YVAD-CMK is invaluable for research applications focused on cell death pathways and inflammatory responses. It is particularly useful in studies investigating the role of caspases in disease models, including neurodegeneration and cancer. -
MMP-3/Caspase-1 Inhibitor
Berkeleyamide B is a dual inhibitor of matrix metalloproteinase-3 (MMP-3) and caspase-1, targeting key enzymes involved in inflammation and tissue remodeling. This compound demonstrates significant biological activity in modulating apoptotic pathways and inflammatory responses. Berkeleyamide B is applicable in research focused on cancer and inflammatory diseases, including conditions such as rheumatoid arthritis. -
Caspase-3 Inhibitor
Caspase-3-IN-3 is a selective inhibitor of caspase-3, a crucial executioner enzyme in the apoptosis pathway. This compound has been shown to enhance cellular ATP levels, inhibit caspase-3 activity, and reduce nitrite production. Additionally, Caspase-3-IN-3 mitigates cytokine-induced apoptosis and restores insulin secretion stimulated by glucose, making it a valuable tool for research in apoptosis, metabolic disorders, and cellular energy regulation. -
Caspase-3 Inhibitor
Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone is a potent and cell-permeable inhibitor of caspase-3, acting through irreversible binding to the activated form in apoptotic cells. This reagent exhibits significant fluorescence, allowing for quantitative analysis via flow cytometry, microwell plate readers, or fluorescence microscopy. Its application is crucial for studying apoptosis and characterizing caspase-3 activity in various biological systems. -
Caspase Inhibitor
VX-166 is a pan caspase inhibitor that modulates apoptosis by targeting caspase enzymes. This compound is instrumental in investigating Non-Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), and alcoholic steatohepatitis (ASH), as well as other conditions characterized by liver fibrosis, steatosis, or inflammation. Its ability to inhibit caspase activity makes it a valuable tool for research in liver pathology and related diseases. -
Caspase 3/7 Inhibitor
CAY10406 is a selective inhibitor of caspase 3 and caspase 7. This compound effectively reduces the expression of the 28-kDa IL-1β fragment, making it useful for studies related to apoptosis and inflammatory processes. Notably, CAY10406 exhibits minimal cytotoxicity at concentrations up to 10 μM, allowing for safer applications in cellular assays. -
MMP-3/Caspase-1 Inhibitor
Berkeleyamide C is a selective inhibitor of matrix metalloproteinase-3 (MMP-3) and caspase-1. This compound effectively blocks MMP-3-mediated tumor cell invasion and metastasis, while also inhibiting the abnormal activation of inflammation and apoptosis associated with caspase-1. Berkeleyamide C is valuable for research applications focused on cancer biology and inflammation-related diseases. -
Caspase-6 Inhibitor
ED11 is a selective inhibitor of caspase-6, demonstrating an IC50 of 12.12 nM. By competing with Huntingtin (Htt) for the active site of caspase-6, ED11 effectively reduces Htt cleavage. Notably, ED11 possesses the ability to cross the blood-brain barrier, making it a valuable reagent for research into Huntington's disease and related neurodegenerative disorders. -
Caspase-9 Inhibitor
Z-LEHD-FMK TFA is a selective and irreversible inhibitor of caspase-9, primarily involved in the apoptosis pathway. This compound demonstrates significant neuroprotective effects, particularly in models of spinal cord injury, and has been shown to mitigate lethal reperfusion injury. It is a valuable tool for research focused on therapeutic strategies against apoptotic cell death and neuroprotection. -
Caspase Inhibitor
Ac-DMQD-CHO is a selective inhibitor of caspase 3, exhibiting an IC50 of 39 nM. This compound effectively reduces apoptosis, making it a valuable tool in studies related to neuroprotection and cellular survival. Its application in research can aid in the exploration of therapeutic strategies targeting neurodegenerative diseases and apoptosis-related conditions. -
Caspase-8 Inhibitor
Z-LE(OMe)TD(OMe)-FMK is a selective inhibitor of caspase-8, a key enzyme involved in the apoptotic pathway. By inhibiting caspase-8 activity, this reagent effectively prevents apoptosis in various cell types, making it a valuable tool for studying cell survival mechanisms. It is widely used in research applications focused on programmed cell death and related signaling pathways. -
Caspase-3 Inhibitor
Ac-DMQD-AMC is a selective inhibitor of caspase-3, a critical executioner caspase in the apoptosis pathway. This compound features an aromatic amine structure and is synthesized using the aminium-based coupling reagent HATU alongside 2,4,6-trimethylpyridine (TMP). Ac-DMQD-AMC is suitable for research applications focused on studying apoptosis, cellular signaling, and the role of caspases in various diseases. -
Caspase-3 Inhibitor
Ac-AAVALLPAVLLALLAP-DEVD-CHO is a specific and reversible inhibitor of caspase-3, a key executioner in the apoptotic pathway. This compound effectively reduces caspase-3 activity, making it a valuable tool for studying apoptosis and cell death mechanisms in various biological contexts. Its application extends to research on neurodegenerative diseases, cancer, and other conditions where caspase-3 plays a pivotal role in cellular regulation. -
Caspase-4 Inhibitor
Ac-AAVALLPAVLLALLAP-LEVD-CHO is a cell-permeable inhibitor of caspase-4, a crucial mediator of inflammation and cell death pathways. This compound demonstrates notable antitumor activity, making it a valuable tool for studying caspase-related mechanisms in cancer research. Its ability to selectively inhibit caspase-4 can provide insights into therapeutic strategies aimed at mitigating inflammatory responses and promoting cell survival. -
Caspase-12 Inhibitor
Z-ATAD-FMK is a selective inhibitor of caspase-12, playing a crucial role in modulating apoptotic processes triggered by endoplasmic reticulum stress. By inhibiting caspase-12 activity, Z-ATAD-FMK effectively reduces downstream activation of caspase-9, thereby interfering with the apoptotic signaling pathways. This compound is valuable for research applications investigating the mechanisms of ER stress-induced apoptosis and cellular responses to stress. -
RIPK2 Inhibitor
RIPK2-IN-7 is a potent and selective inhibitor of RIPK2, exhibiting an IC50 of 0.6 nM. This compound effectively inhibits RIPK2 kinase activity, thereby disrupting the nucleotide-binding oligomerization domain (NOD) signaling pathway and decreasing the production of pro-inflammatory cytokines such as TNFα. RIPK2-IN-7 is a valuable tool for researching inflammatory bowel disease (IBD) and related inflammatory conditions. -
Caspase-1/4 Inhibitor
VRT-043198 is a selective inhibitor of caspase-1 and caspase-4, functioning primarily as an interleukin-converting enzyme inhibitor. It demonstrates potent inhibition with Ki values of 0.8 nM for caspase-1 and 0.6 nM for caspase-4. This compound is capable of crossing the blood-brain barrier, making it valuable for research applications related to neuroinflammation and cytokine regulation. -
Caspase-3 Inhibitor
Caspase-3-IN-1 is a potent inhibitor of caspase-3, exhibiting an IC50 of 14.5 nM. This compound plays a crucial role in the modulation of apoptotic signaling pathways, making it valuable for research in cell death mechanisms and therapeutic applications in cancer and neurodegenerative diseases. Its high specificity and efficacy allow for detailed studies on caspase-3 activity and its implications in various biological processes.
